Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Petra Mináriková"'
Autor:
Ondřej Kučerka, Marie Blahutová, Vít Kosek, Petra Mináriková, Jan M. Horáček, Petr Urbánek, Martin Malý
Publikováno v:
Metabolites, Vol 14, Iss 4, p 185 (2024)
Inflammatory bowel disease, encompassing Crohn’s disease and ulcerative colitis, is a persistent immune-mediated inflammatory gastrointestinal disease. This study investigates the role of growth differentiation factor 15 in severe IBD cases, aiming
Externí odkaz:
https://doaj.org/article/a1fc89fb20fd4eec8c0b17940b21a158
Autor:
Martin Bortlík, Dana Ďuricová, Luděk Hrdlička, Petra Matějková, Aleš Novotný, Pavel Drastich, Václav Mandys, Petra Mináriková, Barbora Pipek, Ivana Kajzrlíková, Lenka Nedbalová, Jana Koželuhová, Naděžda Machková, Vladimír Zbořil, Lucie Prokopová, Pavel Kohout, Zuzana Šerclová, Martin Vašátko, Tomáš Douda, Jiří Stehlík, Karel Mareš, Milan Lukáš
Publikováno v:
Gastroenterologie a hepatologie. 76:13-28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cb375b442101bde1569936457c34354
https://doi.org/10.48095/ccgh202213
https://doi.org/10.48095/ccgh202213
Autor:
Martin Wasserbauer, Stepan Hlava, Jiri Drabek, Jan Stovicek, Petra Minarikova, Lenka Nedbalova, Tomas Drasar, Zdena Zadorova, Jiri Dolina, Stefan Konecny, Vladimír Kojecky, Jana Kozeluhova, Pavlina Cernikova, Dita Pichlerova, Barbora Kucerova, Stepan Coufal, Radan Keil
Publikováno v:
PLoS ONE, Vol 17, Iss 8, p e0271299 (2022)
ObjectiveThe adalimumab biosimilars FKB327 and GP2017 were approved for the therapy of patients with inflammatory bowel disease (IBD). Relatively few prospective studies with biosimilar adalimumab in patients with IBD have been published. The aim of
Externí odkaz:
https://doaj.org/article/604ec382071046c2b523a4e6e4d9cc2d
Autor:
Petra Minarikova, Lucie Benesova, Tereza Halkova, Barbora Belsanova, Inna Tuckova, Frantisek Belina, Ladislav Dusek, Miroslav Zavoral, Marek Minarik
Publikováno v:
Gastroenterology Research and Practice, Vol 2016 (2016)
Background. Gastric cancer is known for a notable variety in the course of the disease. Clinical factors, such as tumor stage, grade, and localization, are key in patient survival. It is expected that molecular factors such as somatic mutations and g
Externí odkaz:
https://doaj.org/article/f73afe54865a4b218fb9985bf696dc54